I stumbled across a company called Personalis Inc. (PSNL) on Wednesday. This cancer genomics company has not been trading for long, but it shows promise.
An extremely bright relative of mine mentioned the company in conversation. You never know where you will get a good idea. Let's check out the charts and indicators of this company.
Personalis' NeXT platform is a precision medicine and machine learning analytic platform that helps pharma companies develop new compounds tailored for each patient. Cutting edge stuff -- and over my pay grade.
In this daily bar chart of PSNL, below, we can see that prices declined into a March low along with the broad market. Prices made a "V" bottom, and have rallied sharply from around $4 to over $24.
Prices are above the rising 50-day moving average line and above the rising 200-day moving average line. A bullish golden cross of these two averages can be seen in the middle of June. The trading volume was active in March at the low and it has been active again since early August. The On-Balance-Volume (OBV) line shows a long rise from December and tells us that buyers of PSNL have been more aggressive. The trend-following Moving Average Convergence Divergence (MACD) oscillator crossed above the zero-line in April for an outright buy signal. Now the MACD oscillator looks like it is crossing to the upside again for a fresh buy signal.